Estonsko - estonština - Ravimiamet

pfizer enterprises sarl - karboplatiin - infusioonilahuse kontsentraat - 10mg 1ml 15ml 1tk; 10mg 1ml 5ml 1tk; 10mg 1ml 45ml 1tk

Estonsko - estonština - Ravimiamet

pfizer enterprises sarl - tolterodiin - õhukese polümeerikattega tablett - 1mg 56tk; 1mg 28tk

Estonsko - estonština - Ravimiamet

pfizer enterprises sarl - alprostadiil - süstelahuse pulber ja lahusti - 20mcg 1tk

Estonsko - estonština - Ravimiamet

pfizer enterprises sarl - tolterodiin - õhukese polümeerikattega tablett - 2mg 28tk; 2mg 56tk

Estonsko - estonština - Ravimiamet

pfizer enterprises sarl - alprostadiil - süstelahuse pulber ja lahusti - 10mcg 1tk

Estonsko - estonština - Ravimiamet

pfizer enterprises sarl - alprasolaam - toimeainet prolongeeritult vabastav tablett - 2mg 30tk

Estonsko - estonština - Ravimiamet

pfizer enterprises sarl - idarubitsiin - kõvakapsel - 10mg 1tk

Estonsko - estonština - Ravimiamet

pfizer enterprises sarl - idarubitsiin - kõvakapsel - 5mg 1tk

Estonsko - estonština - Ravimiamet

pfizer enterprises sarl - irinotekaan - infusioonilahuse kontsentraat - 20mg 1ml 5ml 1tk; 20mg 1ml 15ml 1tk; 20mg 1ml 2ml 1tk

Evropská unie - estonština - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.